AAPL   330.06 (+2.40%)
GOOGL   1,439.79 (+1.80%)
AMZN   2,481.87 (+0.86%)
NVDA   357.01 (+1.81%)
MU   53.94 (+5.31%)
GE   7.88 (+1.68%)
TSLA   883.23 (+2.18%)
AMD   52.95 (+0.61%)
T   32.83 (+3.24%)
ACB   13.88 (-2.46%)
BA   205.00 (+11.23%)
AAPL   330.06 (+2.40%)
GOOGL   1,439.79 (+1.80%)
AMZN   2,481.87 (+0.86%)
NVDA   357.01 (+1.81%)
MU   53.94 (+5.31%)
GE   7.88 (+1.68%)
TSLA   883.23 (+2.18%)
AMD   52.95 (+0.61%)
T   32.83 (+3.24%)
ACB   13.88 (-2.46%)
BA   205.00 (+11.23%)
AAPL   330.06 (+2.40%)
GOOGL   1,439.79 (+1.80%)
AMZN   2,481.87 (+0.86%)
NVDA   357.01 (+1.81%)
MU   53.94 (+5.31%)
GE   7.88 (+1.68%)
TSLA   883.23 (+2.18%)
AMD   52.95 (+0.61%)
T   32.83 (+3.24%)
ACB   13.88 (-2.46%)
BA   205.00 (+11.23%)
AAPL   330.06 (+2.40%)
GOOGL   1,439.79 (+1.80%)
AMZN   2,481.87 (+0.86%)
NVDA   357.01 (+1.81%)
MU   53.94 (+5.31%)
GE   7.88 (+1.68%)
TSLA   883.23 (+2.18%)
AMD   52.95 (+0.61%)
T   32.83 (+3.24%)
ACB   13.88 (-2.46%)
BA   205.00 (+11.23%)
Log in

NASDAQ:EXELExelixis Stock Price, Forecast & News

$22.46
-0.12 (-0.53 %)
(As of 06/5/2020 03:19 PM ET)
Add
Compare
Today's Range
$21.89
Now: $22.46
$23.07
50-Day Range
$18.22
MA: $24.51
$27.42
52-Week Range
$13.67
Now: $22.46
$27.80
Volume1.23 million shs
Average Volume2.98 million shs
Market Capitalization$6.89 billion
P/E Ratio24.15
Dividend YieldN/A
Beta1.5
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Read More
Exelixis logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.10 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$967.78 million
Cash Flow$1.05 per share
Book Value$5.55 per share

Profitability

Net Income$321.01 million

Miscellaneous

Employees484
Market Cap$6.89 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

How has Exelixis' stock been impacted by COVID-19 (Coronavirus)?

Exelixis' stock was trading at $17.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EXEL shares have increased by 29.7% and is now trading at $22.46. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Exelixis?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Exelixis.

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Exelixis.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The biotechnology company had revenue of $226.90 million for the quarter, compared to analysts' expectations of $216.64 million. Exelixis had a return on equity of 18.01% and a net margin of 30.01%. The company's quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.27 earnings per share. View Exelixis' earnings history.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $850-900 million, compared to the consensus revenue estimate of $886.93 million.

What price target have analysts set for EXEL?

12 equities research analysts have issued twelve-month price objectives for Exelixis' stock. Their forecasts range from $21.00 to $40.00. On average, they expect Exelixis' stock price to reach $28.92 in the next year. This suggests a possible upside of 28.7% from the stock's current price. View analysts' price targets for Exelixis.

Has Exelixis been receiving favorable news coverage?

Press coverage about EXEL stock has been trending very negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Exelixis earned a news impact score of -3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View the latest news aboutExelixis.

Are investors shorting Exelixis?

Exelixis saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 16,450,000 shares, a decrease of 16.9% from the April 30th total of 19,790,000 shares. Based on an average trading volume of 4,220,000 shares, the short-interest ratio is presently 3.9 days. Approximately 5.6% of the shares of the company are short sold. View Exelixis' Current Options Chain.

Who are some of Exelixis' key competitors?

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Intel (INTC), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Who are Exelixis' key executives?

Exelixis' management team includes the following people:
  • Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.90%), Meditor Group Ltd (4.72%), State Street Corp (3.70%), JPMorgan Chase & Co. (2.78%), AQR Capital Management LLC (1.81%) and First Trust Advisors LP (1.63%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View institutional ownership trends for Exelixis.

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, BlackRock Inc., Nuveen Asset Management LLC, Meditor Group Ltd, Orbimed Advisors LLC, Squarepoint Ops LLC, Bank of New York Mellon Corp, and Principal Financial Group Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos, and Vincent T Marchesi. View insider buying and selling activity for Exelixis.

Which institutional investors are buying Exelixis stock?

EXEL stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Janus Henderson Group PLC, Blair William & Co. IL, Samlyn Capital LLC, JPMorgan Chase & Co., First Trust Advisors LP, MERIAN GLOBAL INVESTORS UK Ltd, and Mackay Shields LLC. View insider buying and selling activity for Exelixis.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $22.46.

How big of a company is Exelixis?

Exelixis has a market capitalization of $6.89 billion and generates $967.78 million in revenue each year. The biotechnology company earns $321.01 million in net income (profit) each year or $1.02 on an earnings per share basis. Exelixis employs 484 workers across the globe.

What is Exelixis' official website?

The official website for Exelixis is www.exelixis.com.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.